FDA Targets Blood-Zapping Devices in Cancer Fight
Published Date: 3/18/2026
Proposed Rule
Summary
The FDA is planning to require companies that make blood irradiators used during cancer surgeries to get special approval before selling them. This change helps make sure these devices are safe and effective in preventing cancer spread. If finalized, manufacturers will have about 30 months to submit their approval applications, so they should get ready soon!
Analyzed Economic Effects
4 provisions identified: 0 benefits, 3 costs, 1 mixed.
PMA requirement for blood irradiators
If finalized, manufacturers of blood irradiators used to irradiate intraoperatively salvaged blood to help prevent metastasis must file a premarket approval (PMA). The PMA must be filed by the last day of the 30th calendar month after the device is classified into class III.
Market removal and investigational use rules
If a PMA is not timely filed, the device could be deemed adulterated and subject to enforcement, and manufacturers must stop distribution if a PMA is denied. Devices may only be distributed for investigational use under an approved investigational device exemption (IDE).
PMA must include clinical evidence and testing
FDA requires a PMA to include valid scientific evidence, full preclinical and clinical reports, and performance testing showing reasonable assurance of safety and effectiveness. FDA also encourages early meetings via the Q-Submission Program and recommends submitting an IDE at least 30 days before the PMA filing date to avoid interrupting investigations.
Short review window, continued marketing if timely filed
FDA says it intends to review any PMA for these devices within 180 days. A device that was in commercial distribution before May 28, 1976 (or found substantially equivalent by that date) may remain on the market during FDA's PMA review if a PMA is filed on time.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2026-05320 — Medical Devices; Radiology Devices; Classification of Blood Irradiators
The FDA is proposing new rules to make blood irradiators safer and more reliable. Devices that stop a serious transfusion problem will need a simpler review, while those aimed at preventing cancer spread will face a tougher approval process. If you make or use these devices, get ready to comment by May 18, 2026, and expect some extra costs for the stricter reviews.
Next: 2026-05327 — Airworthiness Directives; The Boeing Company Airplanes
If you fly or fix Boeing 787 planes, listen up! The FAA wants to update safety rules by swapping out a part on the wing’s leading edge to keep flights safer and add new maintenance checks. These changes keep all the old safety steps but add new ones, and comments are open until May 4, 2026—so there’s time to weigh in before any costs or work changes kick in.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in